OAG
GILD icon

Oakmont Advisory Group’s Gilead Sciences GILD Stock Holding History

Oakmont Advisory Group’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$333K Buy
2,639
+288
+12% +$37.9K 0.28% 99
2026
Q1 		$328K Sell
2,351
-380
-14% -$53.2K 0.33% 83
2025
Q4 		$335K Buy
+2,731
New +$332K 0.36% 78

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Oakmont Advisory Group's GILD Position: Q2 2026 in Review

Oakmont Advisory Group increased its Gilead Sciences (GILD) stake by 12% in Q2 2026, buying an estimated $37.9K and bringing the position to 2,639 shares worth $333K. The position accounts for 0.28% of the portfolio, ranked #99.

Oakmont Advisory Group first reported a position in GILD in Q4 2025 and has held it in 3 quarters since. The position peaked at $335K in Q4 2025. 2,261 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Oakmont Advisory Group held 2,639 shares of Gilead Sciences worth $333K as of Q2 2026.
  • Oakmont Advisory Group bought 288 Gilead Sciences shares in Q2 2026, an estimated $37.9K.
  • Gilead Sciences made up 0.28% of Oakmont Advisory Group's portfolio in Q2 2026, its #99 holding.
  • Oakmont Advisory Group first reported a position in Gilead Sciences in Q4 2025 and has held it in 3 quarters since.
  • Oakmont Advisory Group's Gilead Sciences position peaked at $335K in Q4 2025.
  • 2,261 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Oakmont Advisory Group's 13F filing for Q2 2026, filed 3 Aug 2026.